BMO Capital Reiterates Outperform Rating on Novo Nordisk (NVO)
Tweet Send to a Friend
BMO Capital analyst Evan Seigerman reiterated an Outperform rating and $105.00 price target on Novo Nordisk (NYSE: NVO).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
